Retina

Ultrasonic retinal prosthesis has been achieved by a research group at UCLA. It is a step towards a non-invasive retinal prosthesis that works without invasive eye surgery.

Lisa M. Nijm, MD, JD, previews the program for this April 2 virtual event designed to help young ophthalmologists learn everything they need to know when starting practice.

Ultrasonic retinal prosthesis has been achieved by a research group at UCLA. It is a step towards a non-invasive retinal prosthesis that works without invasive eye surgery.

Investigators studying old flies have gained some new insight into retinal degeneration, seeking an understanding "of the molecular mechanisms that drive age-associated changes and the external and internal factors that influence them.”

This new surgical technique offers precision down to the micron level, which is more precise than a surgeon can achieve by themselves.

Trial recruitment is enabled by the Foundation Fighting Blindness' patient registry, My Retina Tracker Registry, which includes gene

The clinical trial will evaluate the safety and tolerability of ADX-2191 in patients diagnosed with RP due to mutations of the rhodopsin gene, including the P23H gene mutation.

Rich Small, CEO of Neurotech, provides updates on the company’s pipeline that is the culmination of nearly 2 decades of research.

Christina Y. Weng, MD, MBA, an associate professor of ophthalmology and surgical retina fellowship program director at Baylor College of Medicine in Houston, recently shared some standout therapies for macular degeneration.

Dr. Aleksandra Rachitskaya discusses how the treatment landscape for Inherited Retinal Diseases has changed and her hope for the future.

Dr Aleksandra Rachitskaya discusses how the treatment landscape for Inherited Retinal Diseases has changed and her hope for the future.

Aleksandra Rachitskaya, MD, discusses how the treatment landscape for inherited retinal diseases has changed and her hope for the future.

While there is currently no cure for blindness, an artificial vision system has undergone its first successful implantation, bringing with it the potential to restore partial vision to people who have lost their sight.

Alimera Sciences, Inc. announces statistically significant improvements in best corrected visual acuity, central subfield thickness and treatment burden for patients with diabetic macular oedema.

Dr Quan Dong Nguyen reviews a Monte Carlo simulation that showed evidence that treating severe NPDR with anti-VEGF therapy garners positive results.

Dr. Quan Dong Nguyen reviews a Monte Carlo simulation that showed evidence that treating severe NPDR with anti-VEGF therapy garners positive results.

KSI-301, a therapy for patients with nAMD, did not meet the primary endpoint of showing non-inferior visual acuity gains compared to aflibercept given every eight weeks, however it was safe and well tolerated with no new or unexpected safety signals.

While there is currently no cure for blindness, an artificial vision system has undergone its first successful implantation, bringing with it the potential to restore partial vision to people who have lost their sight.

Researchers know that parts of the retina are considered as biomarkers for Alzheimer disease, but the team from Otago’s Dunedin Multidisciplinary Health and Development Research Unit in New Zealand have been investigating the retina’s potential to indicate cognitive change earlier in life.

Tiffani Martin was diagnosed with type 1 juvenile diabetes when she was just 5 years old, and has battled myriad health issues as a result, including vision loss. Leading the charge for a multifactorial approach to combat diabetes, Kristen Nwanyanwu, MD, MBA, MHS, and her team have embraced the need for a multi-pronged program to address health disparities in diabetic retinopathy.

Kriya Therapeutics company recently took the wraps off an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.

At Angiogenesis, Dr. David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.

The company recently took the wraps off an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.